Family Capital Management Inc. Acquires Shares of 30,610 Pfizer Inc. $PFE

Family Capital Management Inc. acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 30,610 shares of the biopharmaceutical company’s stock, valued at approximately $742,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the 1st quarter valued at about $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. North Capital Inc. acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.6%

Pfizer stock opened at $24.84 on Wednesday. The company’s 50 day simple moving average is $24.89 and its 200 day simple moving average is $24.13. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The firm has a market capitalization of $141.23 billion, a price-to-earnings ratio of 13.21, a PEG ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.